Legal action against GSK over SSRI data

Sibbald, Barbara
July 2004
CMAJ: Canadian Medical Association Journal;7/6/2004, Vol. 171 Issue 1, p23
Academic Journal
Focuses on a lawsuit filed by New York State Attorney General Eliot Spitzer against GlaxoSmithKline (GSK) over its alleged failure to disclose important safety and efficacy information concerning the use of its antidepressant paroxetine by minors. Result of a clinical trial on the effect of paroxetine on adolescents; Basis of Spitzer for filing a consumer fraud lawsuit against GSK; Statement from GSK about the issue.


Related Articles

  • THE STATE OF NEW YORK V. GLAXOSMITHKLINE.  // Multinational Monitor;Jul/Aug2004, Vol. 25 Issue 7/8, p38 

    Focuses on the lawsuit filed by New York Attorney General Eliot Spitzer against drug manufacturer GlaxoSmithKline (GSK) for the alleged suppression of clinical study information exhibiting the effectivity of placebo over the anti-depressant paroxetine in children. Response of the company...

  • The sounds of silence.  // Nature Medicine;Jul2004, Vol. 10 Issue 7, p653 

    Presents an editorial that focuses on New York State Attorney General Eliot Spitzer's lawsuit against GlaxoSmithKline (GSK) for repeated and persistent fraud. Contention of Spitzer that the company failed to disclose information on the safety and efficacy of paroxetine for the treatment of...

  • Spitzer Calls Lawsuit by OCC 'Shameful'. Bergman, Hannah // American Banker;6/20/2005, Vol. 170 Issue 117, p24 

    The article focuses on New York Attorney General Eliot Spitzer. Spitzer said Friday that the lawsuit the Office of the Comptroller of the Currency filed against him is "shameful." The suit, filed Thursday in the U.S. District Court for the Southern District of New York, seeks to block Spitzer's...

  • Spitzer Probes Will Have Benefits, CIAB Chair Says. Ruquet, Mark E. // National Underwriter / P&C;10/17/2005, Vol. 109 Issue 39, p6 

    Reports on the actions of Eliot Spitzer, Attorney General, with regards to his charges against the insurance industry in New York. Statement from the chairman of the Council of Insurance Agents and Brokers (CIAB)about the benefits gained from the charges; Opening of the CIABs annual insurance...

  • Broker-insurer ties on workforce radar. Kranz, Garry // Workforce Management;Dec2004, Vol. 83 Issue 13, p23 

    Discusses the issue behind the widening investigation of sales-incentive tactics in the insurance industry that forces companies to consider fee arrangements they have with benefits-related insurance brokers and insurers. Result of the arrangement between insurers and brokers; Statement issued...

  • Biggest Buyers Opt-In To Marsh Settlement. Ruquet, Mark E. // National Underwriter / P&C;10/3/2005, Vol. 109 Issue 37, p8 

    Reports on the election of eligible policyholders to participate in the multimillion dollar settlement of Marsh & McLennan Cos. Inc. with New York Attorney General Eliot Spitzer and Superintendent of Insurance Howard Mills. Objectives of the settlement program; Amount of the settlement;...

  • Spitzer probe to boost transparency of placements. Parekh, Rupal // Business Insurance;11/29/2004, Vol. 38 Issue 48, p22 

    The article discusses the changes that the New York Attorney General Eliot Spitzer's fraud and antitrust lawsuit against Marsh & McLennan Cos. Inc. will initiate for the U.S. insurance industry. Insurance buyers, who had trusted their advisors, discovered that some of those advisers had violated...

  • U.S. Judge Continues Freedom Holdings Tobacco Settlement Case to June 2. Albanese, Elizabeth // Bond Buyer;5/26/2004, Vol. 348 Issue 31892, p7 

    Reports that a motion seeking a summary judgment declaring the 1998 tobacco Master Settlement Agreement illegal was continued on May 24, 2004 until June 2, 2004 by a federal district court in New York City. Lawsuit filed by Freedom Holdings and other small tobacco manufacturers against New York...

  • GSK: see you in court, again.  // PharmaWatch: CNS;August 2004, Vol. 3 Issue 8, p16 

    A lawsuit alleging that GlaxoSmithKline PLC's (GSK) Seroxat (paroxetine) is a defective product under the Consumer Protection Act will be the latest in a string of legal cases concerning the drug. Lawyers representing the UK Seroxat Users Group are planning to launch a multi-million pound...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics